From 2001 to 2004 Orbinski co-chaired MSF's Neglected Diseases Working Group, which created and launched the Drugs for Neglected Diseases Initiative (DNDi). The DNDi is a global not-for-profit research consortia focused on developing treatments for tropical diseases of the developing world that are largely neglected by profit driven research and development companies. Since its inception, the DNDi has engaged significant international advocacy for neglected tropical diseases, and moreover developed and disseminated two antimalarial treatments, one new treatment against sleeping sickness, one new treatment against Visceral leishmaniasis, a set of treatments for Visceral leishmaniasis in Asia, and a pediatric dosage formulation for Chagas Disease. These new drugs are now available to millions of people. DNDi also has a development portfolio of over 30 lead compounds targeting neglected diseases.